Sahaj Madhav, MBA

Sahaj Madhav is a Director on the Transactions team within the BD group at Amgen. He is responsible for corporate development activities including strategic collaborations, M&A, licensing/out-licensing activities and equity investments. Sahaj was the transactions lead for the proposed acquisition of Horizon Therapeutics for $28.3B, the largest deal in Amgen’s history, pending close. He led a number of outbound transactions to create new companies NewAmsterdam Pharma (NASDAQ: NAMS), Vigil Neuroscience (NASDAQ: VIGL) and Neumora Therapeutics formed by Forbion, Atlas Ventures and Arch Ventures respectively. He led the research collaboration deals with Generate Biomedicines and Synaffix, the acquisition of Rodeo Therapeutics and played an integral role in the $13.4B asset acquisition of Otezla® from BMS/Celgene. Sahaj previously held roles on the valuation team in Business Development, as a U.S. revenue planner for Prolia® & EVENITY®, and supported the strategic financial and accounting analysis related to Amgen’s restructuring in 2014. Sahaj holds a B.S. degree in Chemical Engineering from UCLA and an MBA from the Tepper School of Business at Carnegie Mellon.